AEON Biopharma (AEON) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 17, 2026, with voting available online or in person until June 16, 2026.
Proxy materials, including the Proxy Statement and Form 10-K, are accessible online or by request.
Voting matters and shareholder proposals
Shareholders will vote on the election of two director nominees: Marc Forth and Seongsoo Park.
Ratification of KPMG LLP as the independent registered public accounting firm for 2026 is on the agenda.
Additional business may be addressed if properly brought before the meeting.
Board of directors and corporate governance
Board recommends voting in favor of both director nominees and the auditor ratification.
Partial view of Summaries dataset, powered by Quartr API
Latest events from AEON Biopharma
- ABP-450 aims to be the first full-label BOTOX® biosimilar, unlocking broad market adoption.AEON
Corporate presentation - Q2 2026 net loss narrowed to $1.2M, but cash burn and dilution risks persist.AEON
Q2 2026 - Registration amended for higher-priced Class A shares and warrants, with updated underwriter details.AEON
Registration filing - Raises $11M via equity and warrants to fund biosimilar development, but faces major financial risk.AEON
Registration filing - ABP-450 aims to disrupt BOTOX®'s dominance with full-label biosimilarity and broad market access.AEON
Corporate presentation - Q1 2026 net loss was $11.8M; positive FDA feedback and debt reduction support future plans.AEON
Q1 2026 - Shareholders will vote on director elections and auditor ratification, with Daewoong as a key stakeholder.AEON
Proxy filing - Positive biosimilarity results, FDA support, and improved liquidity position ABP-450 for next steps.AEON
Q4 2025 - ABP-450 targets BOTOX's dominance with a clinically identical, cost-saving biosimilar.AEON
Corporate presentation